Jerome Riebman - 08 Sep 2022 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Jeffrey Hamet, Attorney-in-Fact for Jerome Riebman
Issuer symbol
ELUT
Transactions as of
08 Sep 2022
Net transactions value
-$37,259
Form type
4
Filing time
12 Sep 2022, 17:01:50 UTC
Previous filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELUT Class A Common Stock Options Exercise +14,758 +277% 20,093 08 Sep 2022 Direct F1, F2
transaction ELUT Class A Common Stock Tax liability $37,259 -5,104 -25% $7.30* 14,989 08 Sep 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELUT Restricted Stock Units Options Exercise $0 -14,758 -100% $0.000000* 0 08 Sep 2022 Class A Common Stock 14,758 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.
F2 Includes one share of the Issuer's Class A Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3 Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.
F4 The restricted stock units granted on March 8, 2022 vested in full on September 8, 2022.